(Q33538682)

27 July 2017

1 reference

title

New antivirals - mechanism of action and resistance development (English)

1 reference

ORCID Public Data File 2021

27 July 2017

1 reference

author name string

Balzarini J

series ordinal

1

1 reference

27 July 2017

Naesens L

series ordinal

2

1 reference

27 July 2017

De Clercq E

series ordinal

3

1 reference

27 July 2017

publication date

1 October 1998

1 reference

Current Opinion in Microbiology

27 July 2017

published in

1 reference

27 July 2017

volume

1

1 reference

27 July 2017

issue

5

1 reference

27 July 2017

page(s)

535-546

1 reference

A preliminary trial of lamivudine for chronic hepatitis B infection

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

1 reference

7 January 2021

In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Development of a point mutation assay for the detection of human cytomegalovirus UL97 mutations associated with ganciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Clinical uses of cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recov

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options

1 reference

https://api.crossref.org/works/10.1016%2FS1369-5274%2898%2980086-6

7 January 2021

10.1016/S1369-5274(98)80086-6

Identifiers

DOI

1 reference

27 July 2017

1 reference